Bill Text: CA SB473 | 2021-2022 | Regular Session | Amended
Bill Title: Health care coverage: insulin cost sharing.
Spectrum: Bipartisan Bill
Status: (Engrossed - Dead) 2022-08-11 - August 11 hearing: Held in committee and under submission. [SB473 Detail]
Download: California-2021-SB473-Amended.html
|
Amended
IN
Assembly
June 16, 2022 |
|
Amended
IN
Senate
January 13, 2022 |
|
Amended
IN
Senate
January 03, 2022 |
|
Amended
IN
Senate
March 10, 2021 |
CALIFORNIA LEGISLATURE—
2021–2022 REGULAR SESSION
Senate Bill
No. 473
| Introduced by Senator Bates (Coauthor: Senator Rubio) |
February 17, 2021 |
An act to amend Section 1367.51 of the Health and Safety Code, and to amend Section 10176.61 of the Insurance Code, relating to health care coverage.
LEGISLATIVE COUNSEL'S DIGEST
SB 473, as amended, Bates.
Health care coverage: insulin cost sharing.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act’s requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, to include coverage for equipment, supplies, and, if the contract or policy covers prescription benefits, prescriptive medications for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes, as medically necessary.
This bill would prohibit
require a health care service plan contract or a health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2023, from imposing cost sharing on a covered insulin prescription, except to cover all available dosage forms and concentrations of at least one insulin product of each insulin type for a copayment not to exceed $35 per month per each dosage form of insulin products. for a monthly supply, or a multiple of $35 for a multimonth supply, and would prohibit a policy or contract from imposing other cost-sharing requirements. The bill would also prohibit a health
care service plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2023, from imposing a deductible requirement on benefits related to managing and treating diabetes, as specified. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: YESBill Text
The people of the State of California do enact as follows:
SECTION 1.
The Legislature finds and declares that:(a) Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(b) Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(c) Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(d) One in four people using insulin have reported insulin underuse
due to the high cost of insulin.
(e) Diabetes is the seventh leading cause of death and a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(f) Studies have shown that managing diabetes can prevent the complications associated with diabetes.
(g) Therefore, it is important to enact policies to reduce the costs for Californians with diabetes to obtain life-saving and life-sustaining insulin.
SEC. 2.
Section 1367.51 of the Health and Safety Code is amended to read:1367.51.
(a) A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:(1) Blood glucose monitors and blood glucose testing strips.
(2) Blood glucose monitors designed to assist the visually impaired.
(3) Insulin pumps and all related necessary supplies.
(4) Ketone urine testing strips.
(5) Lancets and lancet puncture devices.
(6) Pen delivery systems for the administration of insulin.
(7) Podiatric devices to prevent or treat diabetes-related complications.
(8) Insulin syringes.
(9) Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b) A health care service plan contract,
except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription drug benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1) Insulin.
(2) Prescriptive medications for the treatment of diabetes.
(3) Glucagon.
(c) The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d) (1) Notwithstanding subdivision (c), for a health care service plan contract that is issued, amended, delivered, or renewed on or after January 1, 2023, the copayment for an insulin prescription covered pursuant to subdivision (b) shall not exceed thirty-five dollars ($35) per month per each dosage form of insulin products. shall cover all available dosage forms and concentrations of at least one insulin product of each insulin type for a copayment of no more than thirty-five dollars ($35) for a monthly supply. If a contract covers prescription drugs in larger amounts than a monthly supply, the copayment on that amount shall
be equal to or less than the multiple of the monthly supply copayment, so that the respective copayment for a 60-day or 90-day supply shall not exceed seventy dollars ($70) or one hundred five dollars ($105).
(2) A health care service plan contract that is issued, amended, delivered, or renewed on or after January 1, 2023, shall not impose a deductible, coinsurance, or other cost-sharing requirement on an insulin prescription, prescription covered pursuant to paragraph (1), except for a copayment subject to the limitations in paragraph (1).
(3)Paragraphs (1) and (2) shall only apply to one of each dosage form and insulin type.
(3) For purposes of this subdivision:
(A) “Dosage form” means the form in which insulin is packaged, including vial and pen delivery device.
(B) “Insulin type” means rapid-acting, short-acting, intermediate-acting, or long-acting insulin.
(4)
(e) A health care service plan contract that is issued, amended, delivered, or renewed on or
after January 1, 2023, shall not impose a deductible requirement on a benefit described in subdivision (a). If a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible requirement on a benefit described in paragraph (1) or (2) of subdivision (a), or any other benefit described in subdivision (a) for which the Internal Revenue Service has indicated that the minimum deductible may be waived in a high deductible health plan.
(e)
(f) A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollee’s participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(f)
(g) The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (e) (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent
hospitalizations and complications.
(g)
(h) The copayments for the benefits specified in subdivision (e) (f) shall not exceed those established for physician office visits by the plan.
(h)
(i) A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plan’s evidence of coverage and disclosure contract forms.
(i)
(j) A health care service plan shall not reduce or eliminate coverage as a result of this section.
(j)
(k) This section does not deny or restrict the department’s authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
SEC. 3.
Section 10176.61 of the Insurance Code is amended to read:10176.61.
(a) A health insurance policy issued, amended, or renewed on or after January 1, 2000, shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:(1) Blood glucose monitors and blood glucose testing strips.
(2) Blood glucose monitors designed to assist the visually impaired.
(3) Insulin pumps and all related necessary supplies.
(4) Ketone urine testing strips.
(5) Lancets and lancet puncture devices.
(6) Pen delivery systems for the administration of insulin.
(7) Podiatric devices to prevent or treat diabetes-related complications.
(8) Insulin syringes.
(9) Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b) A health insurance policy that is issued, amended, or renewed on or after January 1, 2000, that covers prescription
drug benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1) Insulin.
(2) Prescriptive medications for the treatment of diabetes.
(3) Glucagon.
(c) The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d) (1) Notwithstanding subdivision (c), for a health insurance policy that is
issued, amended, or renewed on or after January 1, 2023, the copayment for an insulin prescription covered pursuant to
subdivision (b) shall not exceed thirty-five dollars ($35) per month per each dosage form of insulin products. shall cover all available dosage forms and concentrations of at least one insulin product of each insulin type for a copayment of no more than thirty-five dollars ($35) for a monthly supply. If a policy covers prescription drugs in larger amounts than a monthly supply, the copayment on that amount shall be equal to or less than the multiple of the monthly supply copayment, so that the respective copayment for a 60-day or 90-day supply shall not exceed seventy dollars ($70) or one hundred five dollars ($105).
(2) A health insurance policy that is issued, amended, or renewed on or after January 1, 2023, shall not impose a deductible, coinsurance, or other cost-sharing requirement on an
insulin prescription, prescription covered pursuant to paragraph (1), except for a copayment subject to the limitations in paragraph (1).
(3)Paragraphs (1) and (2) shall only apply to one of each dosage form and insulin type.
(3) For purposes of this subdivision:
(A) “Dosage form” means the form in which insulin is packaged, including vial and
pen delivery device.
(B) “Insulin type” means rapid-acting, short-acting, intermediate-acting, or long-acting insulin.
(4)
(e) A health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2023, shall not impose a deductible requirement on a benefit described in subdivision (a). If a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a
deductible requirement on a benefit described in paragraph (1) or (2) of subdivision (a), or any other benefit described in subdivision (a) for which the Internal Revenue Service has indicated that the minimum deductible may be waived in a high deductible health plan.
(e)
(f) A health insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education,
and medical nutrition therapy upon the direction or prescription of those services by the insured’s participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(f)
(g) The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (e)
(f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(g)
(h) The coinsurances and deductibles for the benefits specified in subdivision (e)
(f) shall not exceed those established for physician office visits by the insurer.
(h)
(i) A health insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurer’s evidence of coverage and disclosure policy forms.
(i)
(j) A health insurer shall not reduce or eliminate coverage as a result of this section.
(j)
(k) This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are
covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
